Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Restless legs syndrome is a common neurological condition affecting a substantial portion of the population. It can be an idiopathic disorder, or one that is secondary to another cause. Given that the underlying pathophysiology of restless legs syndrome is not well understood, several drug classes have been studied for symptom control. While dopamine agonists have long been the mainstay of first-line treatment for restless legs syndrome, recently, the α2δ ligands have been increasingly used. These agents have proven both efficacious and safe in a number of clinical trials. Additionally, compared with the dopamine agonists, they have been associated with less augmentation, a phenomenon whereby symptoms emerge earlier in the day, become more severe, and may spread to areas of the body previously unaffected. Newer clinical guidelines for restless legs syndrome are increasingly recommending the α2δ ligands as a logical first-choice medication for patients needing drug therapy for symptom control.

Original languageEnglish (US)
Pages (from-to)149-159
Number of pages11
JournalCNS Drugs
Volume32
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Restless Legs Syndrome
Dopamine Agonists
Ligands
Clinical Trials
Guidelines
Drug Therapy
Pharmaceutical Preparations
Population
Restless legs syndrome 2
Therapeutics

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease. / Faulkner, Michele A.

In: CNS Drugs, Vol. 32, No. 2, 01.02.2018, p. 149-159.

Research output: Contribution to journalReview article

@article{4b9b199e31ed411ebbe18ebf8245920a,
title = "Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease",
abstract = "Restless legs syndrome is a common neurological condition affecting a substantial portion of the population. It can be an idiopathic disorder, or one that is secondary to another cause. Given that the underlying pathophysiology of restless legs syndrome is not well understood, several drug classes have been studied for symptom control. While dopamine agonists have long been the mainstay of first-line treatment for restless legs syndrome, recently, the α2δ ligands have been increasingly used. These agents have proven both efficacious and safe in a number of clinical trials. Additionally, compared with the dopamine agonists, they have been associated with less augmentation, a phenomenon whereby symptoms emerge earlier in the day, become more severe, and may spread to areas of the body previously unaffected. Newer clinical guidelines for restless legs syndrome are increasingly recommending the α2δ ligands as a logical first-choice medication for patients needing drug therapy for symptom control.",
author = "Faulkner, {Michele A.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s40263-018-0502-z",
language = "English (US)",
volume = "32",
pages = "149--159",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease

AU - Faulkner, Michele A.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Restless legs syndrome is a common neurological condition affecting a substantial portion of the population. It can be an idiopathic disorder, or one that is secondary to another cause. Given that the underlying pathophysiology of restless legs syndrome is not well understood, several drug classes have been studied for symptom control. While dopamine agonists have long been the mainstay of first-line treatment for restless legs syndrome, recently, the α2δ ligands have been increasingly used. These agents have proven both efficacious and safe in a number of clinical trials. Additionally, compared with the dopamine agonists, they have been associated with less augmentation, a phenomenon whereby symptoms emerge earlier in the day, become more severe, and may spread to areas of the body previously unaffected. Newer clinical guidelines for restless legs syndrome are increasingly recommending the α2δ ligands as a logical first-choice medication for patients needing drug therapy for symptom control.

AB - Restless legs syndrome is a common neurological condition affecting a substantial portion of the population. It can be an idiopathic disorder, or one that is secondary to another cause. Given that the underlying pathophysiology of restless legs syndrome is not well understood, several drug classes have been studied for symptom control. While dopamine agonists have long been the mainstay of first-line treatment for restless legs syndrome, recently, the α2δ ligands have been increasingly used. These agents have proven both efficacious and safe in a number of clinical trials. Additionally, compared with the dopamine agonists, they have been associated with less augmentation, a phenomenon whereby symptoms emerge earlier in the day, become more severe, and may spread to areas of the body previously unaffected. Newer clinical guidelines for restless legs syndrome are increasingly recommending the α2δ ligands as a logical first-choice medication for patients needing drug therapy for symptom control.

UR - http://www.scopus.com/inward/record.url?scp=85042540227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042540227&partnerID=8YFLogxK

U2 - 10.1007/s40263-018-0502-z

DO - 10.1007/s40263-018-0502-z

M3 - Review article

VL - 32

SP - 149

EP - 159

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 2

ER -